Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04024332
Recruitment Status : Not yet recruiting
First Posted : July 18, 2019
Last Update Posted : July 18, 2019
Sponsor:
Information provided by (Responsible Party):
Idorsia Pharmaceuticals Ltd.

Brief Summary:
Study of the way the body takes up, distributes, and gets rid of ACT-541468 in subjects with abnormal kidney function compared to healthy subjects

Condition or disease Intervention/treatment Phase
Renal Insufficiency Healthy Drug: ACT-541468 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-center, open-label, single-dose study
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Single-center, Open-label, Single-dose Study to Investigate the Pharmacokinetics of ACT-541468 in Subjects With Severe Renal Impairment Compared to Healthy Subjects
Estimated Study Start Date : July 31, 2019
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2020

Arm Intervention/treatment
Experimental: Group A (healthy)
On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
Drug: ACT-541468
ACT-541468 25 mg; administered orally

Experimental: Group B (severe renal function impairment)
On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
Drug: ACT-541468
ACT-541468 25 mg; administered orally




Primary Outcome Measures :
  1. AUC of ACT-541468 from time zero to 24 h after study drug administration (AUC0-inf) [ Time Frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days ]

Secondary Outcome Measures :
  1. Number of subjects with treatment-emergent (serious) adverse events (S)AEs [ Time Frame: During treatment with ACT-541468 administration for a total duration of up to 4 days ]

Other Outcome Measures:
  1. Maximum plasma concentration (Cmax) of ACT-541468 [ Time Frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days ]
  2. Time to reach maximum plasma concentration (tmax) of ACT-541468 [ Time Frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days ]
  3. Terminal half-life (t½) of ACT-541468 [ Time Frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days ]
  4. Extent of plasma protein binding (PPB; in %) [ Time Frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days ]
    PPB % = 100 - (Cu/C×100), with 'Cu' standing for unbound and 'C' for total plasma ACT-541468 concentration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

General inclusion criteria for all subjects:

  • Signed informed consent in the local language prior to any study mandated procedure.
  • Male and female subjects aged 18 to 85 years (inclusive) at screening.
  • Body mass index (BMI) from 18 to 35 kg/m2 (inclusive) at screening. Body weight at least 50 kg.
  • Women of childbearing potential: Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (during the entire study and 30 days thereafter) a highly effective method of contraception with a failure rate of < 1% per year.
  • Women of non-childbearing potential, i.e., postmenopausal, XY genotype, Turner syndrome, uterine agenesis: no contraceptive requirement.

Additional inclusion criteria for healthy subjects (Group A):

  • Normal renal function as confirmed based on Creatinine Clearance (CLcr) by the Cockcroft-Gault equation adjusted for age: >= 80 mL/min for subjects <= 50 years of age; >= 70 mL/min for subjects 51-60 years of age; >= 60 mL/min for subjects 61-85 years of age; CLcr = ([140-age(years)]×weight (kg))/(72×serum creatinine (mg/dL)) (x 0.85 for female subjects)
  • The CLcr value should be confirmed (± 25%) on Day -1 in case subjects will be dosed more than 10 days after the day of screening.
  • Hematology, clinical chemistry, and urinalysis test results not deviating from the normal range to a clinically relevant extent at screening.
  • Each healthy subject must be matched with one subject with severe renal function impairment with regard to age (± 10 years difference allowed), body weight (± 15% difference allowed), and sex, determined by results at screening.

Additional inclusion criteria for subjects with severe renal function impairment (Group B)

  • Severe renal function impairment as confirmed based on CLcr by the Cockcroft-Gault equation: <30 mL/min, not on dialysis.
  • The CLcr value should be confirmed (± 25%) on Day −1 since subjects will be dosed more than 10 days after the day of screening.
  • Hematology, clinical chemistry, coagulation and urinalysis test results consistent with severe renal function impairment at screening.
  • Physical examination without clinically relevant abnormalities at screening and on Day -1 (except for those related to severe renal function impairment), which would interfere with the objectives of the study.
  • Stable concomitant medications.

General exclusion criteria for all subjects:

  • Pregnant or lactating women.
  • Clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
  • History of renal and/or liver transplant.
  • Hepatic cancer, primary biliary cirrhosis or any form of cholestatic disease.
  • Use of drugs which might interfere with the PK of ACT-541468 (moderate to strong CYP3A4 inhibitors or inducers).
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Additional exclusion criteria for healthy subjects (Group A)

  • History or clinical evidence of any unstable disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy, herniotomy, and cholecystectomy allowed).
  • Intake of any creatine supplement from screening to EOS.

Additional exclusion criteria for subjects with severe renal function impairment (Group B).

- End-stage renal disease that requires dialysis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04024332


Contacts
Layout table for location contacts
Contact: Clinical Trials Disclosure Desk +41588441977 clinical-trials-disclosure@idorsia.com

Locations
Layout table for location information
Germany
APEX GmbH Not yet recruiting
München, Germany, 81241
Sponsors and Collaborators
Idorsia Pharmaceuticals Ltd.

Layout table for additonal information
Responsible Party: Idorsia Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT04024332     History of Changes
Other Study ID Numbers: ID-078-115
2019-002159-40 ( EudraCT Number )
First Posted: July 18, 2019    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases